Current position

BlackRock, Inc.’s Eli Lilly (LLY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

BlackRock, Inc.Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2016Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares68.96MHighest verified quarter-end share count
Quarters reported40Verified quarters with shares above zero
What happened?

BlackRock, Inc. first reported Eli Lilly in Q3 2016. The reported position was increased and reduced across later filings. BlackRock, Inc. currently reports 67.54M shares. The latest verified filing showed: Bought 1.7% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 1.7% more+1.16M shares · 67.54M shares reported after the change
Filing context

Quarter-end price $1,199.43

Q1 2026
Baseline
Filing context

Quarter-end price $919.77

Q4 2025
Bought 1.5% more+983.10K shares · 66.79M shares reported after the change
Filing context

Quarter-end price $1,074.68

Q3 2025
Sold 0.2% of the position−151.90K shares · 65.81M shares remained
Filing context

Quarter-end price $763.00

Q2 2025
Bought 0.4% more+269.69K shares · 65.96M shares reported after the change
Filing context

Quarter-end price $779.53

Q1 2025
Bought 0.7% more+462.86K shares · 65.69M shares reported after the change
Filing context

Quarter-end price $825.91

Portfolio importance

How important is Eli Lilly in BlackRock, Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight1.2%Q2 2026
Current rank#12of 5696 reported positions
Peak portfolio weight1.3%Q2 2024
Best historical rank#8Q1 2024
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$1,164.892026-09-21

Market context only; not an investor transaction price.

Latest filing quarter-end price$1,199.43Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-07
Open SEC filing ↗

View Eli Lilly stock page →

Coverage is bounded to BlackRock’s top reported positions and material events rather than every security in each Form 13F. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.